$DVAX
DYNAVAX TECHNOLOGIES CORP

2019 Q4 Form 10-K Financial Statement

#000156459021008833 Filed on February 25, 2021

View on sec.gov

Income Statement

Concept 2019 Q4 2018 Q4 2018
Revenue $10.57M $5.318M $8.198M
YoY Change 98.76% 25223.81% 2407.03%
Cost Of Revenue $4.730M $3.950M $21.80M
YoY Change 19.75%
Gross Profit $5.840M $1.370M -$13.60M
YoY Change 326.28%
Gross Profit Margin 55.25% 25.76% -165.89%
Selling, General & Admin $19.75M $15.98M $64.77M
YoY Change 23.59% 87.12% 136.67%
% of Gross Profit 338.18% 1166.42%
Research & Development $12.27M $22.89M $74.95M
YoY Change -46.4% 31.48% 15.33%
% of Gross Profit 210.1% 1670.8%
Depreciation & Amortization $3.430M $3.430M $14.48M
YoY Change 0.0% 74.11% 226.86%
% of Gross Profit 58.73% 250.36%
Operating Expenses $32.02M $38.87M $161.5M
YoY Change -17.62% 43.17% 67.67%
Operating Profit -$26.18M -$37.50M -$175.1M
YoY Change -30.19% 82.4%
Interest Expense -$11.60M -$1.860M $9.338M
YoY Change 523.66% -450.94% 1161.89%
% of Operating Profit
Other Income/Expense, Net $2.230M -$150.0K -$70.00K
YoY Change -1586.67% 36.36% -85.6%
Pretax Income -$36.76M -$39.97M -$154.6M
YoY Change -8.03% 45.77% 61.22%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$36.76M -$39.97M -$158.9M
YoY Change -8.04% 45.76% 66.99%
Net Earnings / Revenue -347.74% -751.58% -1938.27%
Basic Earnings Per Share -$2.55
Diluted Earnings Per Share -$437.6K -$637.5K -$2.55
COMMON SHARES
Basic Shares Outstanding 62.36M
Diluted Shares Outstanding 62.36M

Balance Sheet

Concept 2019 Q4 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $151.1M $145.5M $145.5M
YoY Change 3.79% -24.14% -24.18%
Cash & Equivalents $39.88M $49.35M $49.30M
Short-Term Investments $111.2M $96.19M $96.20M
Other Short-Term Assets $7.400M $6.100M $6.100M
YoY Change 21.31% 22.0% 22.0%
Inventory $41.33M $19.02M $19.00M
Prepaid Expenses
Receivables $8.900M $3.700M $3.700M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $208.7M $174.4M $174.4M
YoY Change 19.67% -11.95% -11.92%
LONG-TERM ASSETS
Property, Plant & Equipment $32.02M $17.06M $17.10M
YoY Change 87.66% 2.68% 3.01%
Goodwill $2.081M $2.144M
YoY Change -2.94% -4.46%
Intangibles $2.500M $11.72M
YoY Change -78.66%
Long-Term Investments
YoY Change
Other Assets $3.344M $4.976M $5.600M
YoY Change -32.8% 291.81% 194.74%
Total Long-Term Assets $70.42M $36.52M $36.50M
YoY Change 92.81% 75.9% 75.48%
TOTAL ASSETS
Total Short-Term Assets $208.7M $174.4M $174.4M
Total Long-Term Assets $70.42M $36.52M $36.50M
Total Assets $279.1M $210.9M $210.9M
YoY Change 32.33% -3.61% -3.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.278M $5.278M $5.300M
YoY Change 75.79% 16.28% 17.78%
Accrued Expenses $14.80M $16.04M $25.80M
YoY Change -7.72% 65.46% 82.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $53.05M $38.03M $38.00M
YoY Change 39.48% 104.56% 104.3%
LONG-TERM LIABILITIES
Long-Term Debt $178.6M $100.9M $100.9M
YoY Change 77.06%
Other Long-Term Liabilities $1.285M $8.915M $8.900M
YoY Change -85.59% 1286.47% 1383.33%
Total Long-Term Liabilities $179.9M $109.8M $109.8M
YoY Change 63.85% 16974.03% 18200.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.05M $38.03M $38.00M
Total Long-Term Liabilities $179.9M $109.8M $109.8M
Total Liabilities $270.8M $147.8M $147.8M
YoY Change 83.18% 668.45% 669.79%
SHAREHOLDERS EQUITY
Retained Earnings -$1.219B -$1.066B
YoY Change 14.31% 17.51%
Common Stock $1.230B $1.131B
YoY Change 8.68% 2.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.290M $63.07M $63.10M
YoY Change
Total Liabilities & Shareholders Equity $279.1M $210.9M $210.9M
YoY Change 32.33% -3.61% -3.61%

Cashflow Statement

Concept 2019 Q4 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$36.76M -$39.97M -$158.9M
YoY Change -8.04% 45.76% 66.99%
Depreciation, Depletion And Amortization $3.430M $3.430M $14.48M
YoY Change 0.0% 74.11% 226.86%
Cash From Operating Activities -$23.01M -$33.63M -$131.3M
YoY Change -31.58% 89.46% 69.38%
INVESTING ACTIVITIES
Capital Expenditures -$1.830M -$1.350M $4.187M
YoY Change 35.56% 350.0% 525.86%
Acquisitions
YoY Change
Other Investing Activities $26.68M $45.76M $70.65M
YoY Change -41.7% 619.5% -165.4%
Cash From Investing Activities $24.85M $44.42M $55.47M
YoY Change -44.06% 633.0% -151.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 99.07M
YoY Change -100.0% -47.26%
NET CHANGE
Cash From Operating Activities -23.01M -33.63M -131.3M
Cash From Investing Activities 24.85M 44.42M 55.47M
Cash From Financing Activities 0.000 0.000 99.07M
Net Change In Cash 1.840M 10.79M 22.75M
YoY Change -82.95% 68.86% 879.93%
FREE CASH FLOW
Cash From Operating Activities -$23.01M -$33.63M -$131.3M
Capital Expenditures -$1.830M -$1.350M $4.187M
Free Cash Flow -$21.18M -$32.28M -$135.5M
YoY Change -34.39% 84.99% 73.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherCurrentLiabilitiesMember
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherCurrentLiabilitiesMember
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y3M
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y2M15D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y4M6D
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 dvax Prepaid Manufacturing
PrepaidManufacturing
29423000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9206000
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39884000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
111171000
CY2019Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
8886000
CY2019Q4 us-gaap Inventory Net
InventoryNet
41332000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7380000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
290015000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
208653000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30567000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32022000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2500000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26583000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
30252000
CY2020Q4 us-gaap Goodwill
Goodwill
2297000
CY2019Q4 us-gaap Goodwill
Goodwill
2081000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
237000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
216000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3573000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3344000
CY2020Q4 us-gaap Assets
Assets
353272000
CY2019Q4 us-gaap Assets
Assets
279068000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3312000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9278000
CY2020Q4 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2805000
CY2019Q4 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
4120000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35219000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8198000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19099000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14802000
CY2020Q4 dvax Warrant Liability Current
WarrantLiabilityCurrent
10736000
CY2019Q4 dvax Warrant Liability Current
WarrantLiabilityCurrent
14860000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
178601000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34789000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37845000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2568000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
77411000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53047000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1094000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1394000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
179811000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1285000
CY2020Q4 us-gaap Liabilities
Liabilities
294579000
CY2019Q4 us-gaap Liabilities
Liabilities
270778000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
139000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
110190000
CY2020Q4 us-gaap Deferred Revenue
DeferredRevenue
38212000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3247000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9987000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
110190000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83871000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83871000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
110000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
84000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1352374000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1229417000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
273000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2387000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1294064000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1218824000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
58693000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
8290000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
353272000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
279068000
CY2020 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
6851000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-68371000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
3370000
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.16
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.55
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100753000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72024000
CY2020 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
-20000
CY2019 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
140000
CY2018 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
12000
CY2018 us-gaap Interest Expense
InterestExpense
9338000
CY2019 us-gaap Sublease Income
SubleaseIncome
2619000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4124000
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7500000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
731000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-70000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62362000
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.16
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.55
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101504000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72024000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62362000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-158899000
CY2020 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
21000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
199549000
CY2018 dvax Issuance Withholding Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Net Value
IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue
-523000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
594000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23478000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-158899000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
63065000
CY2019 dvax Issuance Withholding Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Net Value
IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue
2000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
565000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
60113000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25456000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-372000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-152600000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
8290000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1000
CY2020 dvax Issuance Withholding Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Net Value
IssuanceWithholdingOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsNetValue
289000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
672000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13484000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2660000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-75240000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
58693000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-158899000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4273000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8938000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3621000
CY2020 dvax Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
2562000
CY2019 dvax Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
3375000
CY2020 dvax Gain On Disposal Of Property And Equipment And Lease Termination
GainOnDisposalOfPropertyAndEquipmentAndLeaseTermination
98000
CY2019 dvax Gain On Disposal Of Property And Equipment And Lease Termination
GainOnDisposalOfPropertyAndEquipmentAndLeaseTermination
-18000
CY2018 dvax Gain On Disposal Of Property And Equipment And Lease Termination
GainOnDisposalOfPropertyAndEquipmentAndLeaseTermination
-98000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-535000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1462000
CY2020 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
57000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4124000
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7500000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
13484000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
25456000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
23478000
CY2020 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
2500000
CY2019 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
9217000
CY2018 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
10862000
CY2020 dvax Non Cash Interest Expense
NonCashInterestExpense
2542000
CY2019 dvax Non Cash Interest Expense
NonCashInterestExpense
4973000
CY2018 dvax Non Cash Interest Expense
NonCashInterestExpense
2755000
CY2020 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
-1137000
CY2019 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
-6999000
CY2020 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
6851000
CY2020 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
13775000
CY2019 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
5182000
CY2018 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
2850000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
22357000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
22310000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
18710000
CY2020 dvax Increase Decrease In Prepaid Manufacturing
IncreaseDecreaseInPrepaidManufacturing
29423000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1826000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1278000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2405000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
229000
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1632000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3706000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3448000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4848000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3417000
CY2020 dvax Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
2872000
CY2019 dvax Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
2000000
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
38212000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2804000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-9376000
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
12597000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-92251000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-121252000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-131301000
CY2020 dvax Payments To Acquire Technology Licenses
PaymentsToAcquireTechnologyLicenses
7000000
CY2019 dvax Payments To Acquire Technology Licenses
PaymentsToAcquireTechnologyLicenses
7000000
CY2018 dvax Payments To Acquire Technology Licenses
PaymentsToAcquireTechnologyLicenses
11000000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30910000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4187000
CY2020 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
6851000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42782000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
55466000
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
74250000
CY2018 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
99000000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
108538000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
65948000
CY2019 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
13586000
CY2020 dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
289000
CY2019 dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
2000
CY2018 dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
-523000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1494000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-184000
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-482000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7790000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9867000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22754000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40100000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49967000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27213000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32310000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40100000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49967000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
16541000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
12147000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
6583000
CY2018 dvax Noncash Or Part Noncash Acquisition Of Technology License
NoncashOrPartNoncashAcquisitionOfTechnologyLicense
12773000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
361000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2698000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
920000
CY2019 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
7360000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
40626000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
165000000.0
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management’s estimates are based on historical information available as of the date of the consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. Actual results could differ materially from these estimates.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our policy is to invest cash in institutional money market funds and marketable securities of the U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We have not experienced any losses on our cash equivalents and marketable securities. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our accounts receivable balance consists, primarily, of amounts due from product sales. Accounts receivable are recorded net of reserves for chargebacks, distribution fees, trade discounts and doubtful accounts. We estimate our allowance for doubtful accounts based on</span><span style="font-size:12pt;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an evaluation of the aging of our receivables. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have not recorded any allowance for doubtful accounts.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates will require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on our business and may impact our business in the future. In addition, after the approval of HEPLISAV-B by the FDA, there is still an ongoing risk of adverse events that did not appear during the drug approval process.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of product candidates, product liability, the volatility of our stock price and the need to obtain additional financing.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020, 2019 and 2018, 77%, 100% and 83%, respectively, of our revenues were earned in the United States. As of December 31, 2020 and 2019, 57% and 62%, respectively, of our long-lived assets were located in the United States and the remaining long-lived assets were located in Germany.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our source of product revenue consists of sales of HEPLISAV-B and CpG 1018. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We sell HEPLISAV-B to a limited number of wholesalers and specialty distributors in the U.S. All of our HEPLISAV-B revenue is from these customers. For the years ended December 31, 2020, 2019 and 2018, our three largest customers collectively represented approximately 61%, 62% and 68% of our HEPLISAV-B product revenue, respectively. All of our CpG 1018 sales were outside the U.S.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, our three largest customers collectively represented approximately 86% and 76% of our HEPLISAV-B trade receivable balance.</p>
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
15198000
CY2019Q3 us-gaap Restructuring Reserve Accelerated Depreciation
RestructuringReserveAcceleratedDepreciation
3000000.0
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1000000.0
CY2020 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2019 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2018 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020Q4 us-gaap Fair Value Equity Level1 To Level2 Transfers Amount
FairValueEquityLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Equity Level1 To Level2 Transfers Amount
FairValueEquityLevel1ToLevel2TransfersAmount
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2020Q4 us-gaap Fair Value Equity Level2 To Level1 Transfers Amount
FairValueEquityLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Equity Level2 To Level1 Transfers Amount
FairValueEquityLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
22890000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8275000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
122156000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
122181000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32073000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39884000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49348000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
237000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
216000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
619000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32310000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40100000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49967000
CY2020Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
165005000
CY2020Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
48000
CY2020Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
17000
CY2020Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
165036000
CY2019Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
150983000
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
84000
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12000
CY2019Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
151055000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3244000
CY2020Q4 us-gaap Inventory Net
InventoryNet
63689000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
10776000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
10782000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
132932000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
132963000
CY2020 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
100000
CY2020 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2019 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2018 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2019 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2018 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
25121000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
30293000
CY2019Q4 us-gaap Inventory Net
InventoryNet
41332000
CY2020Q4 dvax Prepaid Manufacturing
PrepaidManufacturing
29400000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
19773000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
19773000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19773000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
17273000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2500000
CY2020 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2019 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2020Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
13884000
CY2019Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
11484000
CY2020Q4 dvax Laboratory Equipment Gross
LaboratoryEquipmentGross
2888000
CY2019Q4 dvax Laboratory Equipment Gross
LaboratoryEquipmentGross
2522000
CY2020Q4 dvax Computer Equipment Gross
ComputerEquipmentGross
5255000
CY2019Q4 dvax Computer Equipment Gross
ComputerEquipmentGross
5009000
CY2020Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
2510000
CY2019Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
1934000
CY2020Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
28417000
CY2019Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
24724000
CY2020Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
1024000
CY2019Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
4336000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53978000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
50009000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
23411000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17987000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30567000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32022000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4300000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8900000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3600000
CY2019 us-gaap Restructuring Reserve Accelerated Depreciation
RestructuringReserveAcceleratedDepreciation
3000000.0
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8684000
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6653000
CY2020Q4 dvax Revenue Reserve Accrual Current
RevenueReserveAccrualCurrent
6040000
CY2019Q4 dvax Revenue Reserve Accrual Current
RevenueReserveAccrualCurrent
3893000
CY2020Q4 dvax Accrued Third Party Research Expenses Current
AccruedThirdPartyResearchExpensesCurrent
1963000
CY2019Q4 dvax Accrued Third Party Research Expenses Current
AccruedThirdPartyResearchExpensesCurrent
2308000
CY2020Q4 dvax Accrued Third Party Development Expenses Current
AccruedThirdPartyDevelopmentExpensesCurrent
842000
CY2019Q4 dvax Accrued Third Party Development Expenses Current
AccruedThirdPartyDevelopmentExpensesCurrent
505000
CY2019Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
675000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4375000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4888000
CY2020Q4 dvax Accrued Research And Development Expenses And Accrued Liabilities Current
AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent
21904000
CY2019Q4 dvax Accrued Research And Development Expenses And Accrued Liabilities Current
AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent
18922000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
6267000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
6886000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
3953000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
6900000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
5500000
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37845000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
38036000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
40884000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3247000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3039000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34789000
CY2020Q4 dvax Lessor Sublease Rentals Payments To Be Received Next Twelve Months
LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths
5201000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6942000
CY2020Q4 dvax Lessor Sublease Rentals Payments To Be Received Due Year Two
LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo
5357000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6268000
CY2020Q4 dvax Lessor Sublease Rentals Payments To Be Received Due Year Three
LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree
5518000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5403000
CY2020Q4 dvax Lessor Sublease Rentals Payments To Be Received Due Year Four
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour
5684000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5547000
CY2020Q4 dvax Lessor Sublease Rentals Payments To Be Received Due Year Five
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive
5854000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5696000
CY2020Q4 dvax Lessor Sublease Rentals Payments To Be Received Due Thereafter
LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter
33742000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
30760000
CY2020Q4 dvax Lessor Sublease Rentals Payments To Be Received Due
LessorSubleaseRentalsPaymentsToBeReceivedDue
61356000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
60616000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
22580000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
38036000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y8M12D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2020Q4 us-gaap Purchase Obligation
PurchaseObligation
21700000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-75240000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-152600000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-158899000
CY2019 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3267000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-75240000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-155867000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-158899000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4124000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-79364000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-155867000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-158899000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100753000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72024000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62362000
CY2020 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
751000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101504000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72024000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62362000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
110189859
CY2019Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
18525000
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
8005467
CY2020 dvax Proceeds From Cash Received
ProceedsFromCashReceived
32300000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
13800000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
19500000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
8100000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
11.69
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
607000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5551000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.13
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
516000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
26000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
616000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8314000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8006000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.86
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2003000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.76
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
72000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.20
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8505000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.57
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
13484000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
25456000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
23478000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
13484000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
25456000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
23478000
CY2018Q2 dvax Increase In Number Of Employee Stock Purchase Plan Shares Authorized For Issuance
IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance
600000
CY2019Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
80
CY2020 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000
CY2019 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
300000
CY2018 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000
CY2019Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.36
CY2020 us-gaap Restructuring And Related Activities Completion Date
RestructuringAndRelatedActivitiesCompletionDate
2020-12-31
CY2019Q4 us-gaap Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
13356000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-76324000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-154605000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-160032000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1084000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
2005000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1133000
CY2020 dvax Income Loss From Continuing Operations Before Income Taxes
IncomeLossFromContinuingOperationsBeforeIncomeTaxes
-75240000
CY2019 dvax Income Loss From Continuing Operations Before Income Taxes
IncomeLossFromContinuingOperationsBeforeIncomeTaxes
-152600000
CY2018 dvax Income Loss From Continuing Operations Before Income Taxes
IncomeLossFromContinuingOperationsBeforeIncomeTaxes
-158899000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-15756000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-32046000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-33366000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3194000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3153000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-5591000
CY2020 dvax Income Tax Reconciliation Tax Credit
IncomeTaxReconciliationTaxCredit
773000
CY2019 dvax Income Tax Reconciliation Tax Credit
IncomeTaxReconciliationTaxCredit
1757000
CY2018 dvax Income Tax Reconciliation Tax Credit
IncomeTaxReconciliationTaxCredit
3065000
CY2020 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
193000
CY2019 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
5426000
CY2020 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
809000
CY2019 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
4600000
CY2018 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
-1165000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
19009000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
22715000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
43134000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
473000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
2439000
CY2020 dvax Income Tax Rate Reconciliation Mark To Market Of Warrants
IncomeTaxRateReconciliationMarkToMarketOfWarrants
-866000
CY2019 dvax Income Tax Rate Reconciliation Mark To Market Of Warrants
IncomeTaxRateReconciliationMarkToMarketOfWarrants
1575000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
105000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
201000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
53000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
224161000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
207385000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
28578000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
27883000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
17264000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
17312000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
256000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3250000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2437000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
273253000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
255273000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
266100000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
247092000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
7153000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
8181000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
275000
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
275000
CY2020Q4 dvax Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
6878000
CY2019Q4 dvax Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
7906000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
7153000
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
8181000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
19000000.0
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
22300000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10600000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10300000
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10322000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
243000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10565000
CY2020 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
0

Files In Submission

Name View Source Status
0001564590-21-008833-index-headers.html Edgar Link pending
0001564590-21-008833-index.html Edgar Link pending
0001564590-21-008833.txt Edgar Link pending
0001564590-21-008833-xbrl.zip Edgar Link pending
dvax-10k_20201231.htm Edgar Link pending
dvax-10k_20201231_htm.xml Edgar Link completed
dvax-20201231.xsd Edgar Link pending
dvax-20201231_cal.xml Edgar Link unprocessable
dvax-20201231_def.xml Edgar Link unprocessable
dvax-20201231_lab.xml Edgar Link unprocessable
dvax-20201231_pre.xml Edgar Link unprocessable
dvax-ex1031_356.htm Edgar Link pending
dvax-ex1032_132.htm Edgar Link pending
dvax-ex1033_133.htm Edgar Link pending
dvax-ex211_15.htm Edgar Link pending
dvax-ex231_13.htm Edgar Link pending
dvax-ex311_14.htm Edgar Link pending
dvax-ex312_12.htm Edgar Link pending
dvax-ex321_9.htm Edgar Link pending
dvax-ex322_7.htm Edgar Link pending
dvax-ex41_11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gg0ruquvzrax000001.jpg Edgar Link pending
glzcxjxdzte0000001.jpg Edgar Link pending
glzcxjxdzte0000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending